UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of clinical oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 4, pp. 392 - 397
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Blood Transfusion - mortality | Primary Myelofibrosis - mortality | Predictive Value of Tests | Leukemia - blood | Prognosis | Age Factors | Health Status Indicators | Humans | Middle Aged | Male | Primary Myelofibrosis - blood | Young Adult | Time Factors | Cell Transformation, Neoplastic - genetics | Karyotyping | Aged, 80 and over | Adult | Female | Leukocyte Count | Leukemia - genetics | Severity of Illness Index | Primary Myelofibrosis - diagnosis | Reproducibility of Results | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Leukemia - therapy | Chi-Square Distribution | Bone Marrow Examination | Databases as Topic | Disease-Free Survival | Primary Myelofibrosis - genetics | Platelet Count | Adolescent | Leukemia - diagnosis | Aged | Primary Myelofibrosis - therapy | Hemoglobins - analysis | Leukemia - mortality | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 9, pp. 1703 - 1708
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Primary Myelofibrosis - mortality | Prognosis | Age Factors | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Hemoglobins - metabolism | Male | Models, Statistical | Primary Myelofibrosis - blood | Models, Biological | Female | Aged | Leukocyte Count | Primary Myelofibrosis - therapy | Index Medicus | Abridged Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 23 - 34
primary myelofibrosis | myeloproliferative neoplasm | classification | management | prefibrotic myelofibrosis | Life Sciences & Biomedicine | Hematology | Science & Technology | Primary Myelofibrosis - diagnosis | Prognosis | World Health Organization | Humans | Myeloproliferative Disorders - classification | Fibrosis | Primary Myelofibrosis - classification | Disease Management | Primary Myelofibrosis - therapy | Primary Myelofibrosis - pathology | Myelofibrosis | Young adults | Leukemia | Lactate dehydrogenase | Management | Patients | Neoplasms | L-Lactate dehydrogenase | Medical prognosis | Classification | Bone marrow | Thrombocytosis | Adults | Diagnostic systems | Lactic acid | Diagnosis | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 799 - 807
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Primary Myelofibrosis - mortality | Pyrazoles - therapeutic use | Splenomegaly - drug therapy | Follow-Up Studies | Humans | Middle Aged | Male | Spleen - drug effects | Primary Myelofibrosis - pathology | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Adult | Female | Spleen - pathology | Janus Kinase 2 - antagonists & inhibitors | Pyrazoles - adverse effects | Primary Myelofibrosis - drug therapy | Double-Blind Method | Kaplan-Meier Estimate | Organ Size | Janus Kinase 1 - antagonists & inhibitors | Leukemia, Myeloid, Acute - mortality | Cell Transformation, Neoplastic | Protein Kinase Inhibitors - therapeutic use | Intention to Treat Analysis | Quality of Life | Aged | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Myelofibrosis | Drug therapy | Spleen | Thrombocytopenia | Medical research | Transformation | Cytokines | Anemia | Myeloid leukemia | Medical treatment | Clinical trials | Kinases | Survival | Patients | Magnetic resonance imaging | Blood platelets | Janus kinase | Acute myeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 787 - 798
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Primary Myelofibrosis - mortality | Primary Myelofibrosis - drug therapy | Pyrazoles - therapeutic use | Splenomegaly - drug therapy | Follow-Up Studies | Humans | Middle Aged | Organ Size | Male | Spleen - drug effects | Primary Myelofibrosis - pathology | Protein Kinase Inhibitors - adverse effects | Janus Kinase 1 - antagonists & inhibitors | Cause of Death | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Spleen - pathology | Janus Kinase 2 - antagonists & inhibitors | Pyrazoles - adverse effects | Drugs | Enzyme inhibitors | Myelofibrosis | Dosage and administration | Product/Service Evaluations | Drug therapy | Comparative analysis | Spleen | Thrombocytopenia | Splenomegaly | Anemia | Myeloid leukemia | Medical treatment | Polycythemia vera | Patients | Quality of life | Signal transduction | Magnetic resonance imaging | Computed tomography | Polycythemia | Janus kinase | Mutation | Acute myeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Leukemia research, ISSN 0145-2126, 2007, Volume 31, Issue 6, pp. 737 - 740
Hematology, Oncology and Palliative Medicine | IWG-MRT | Primary myelofibrosis | Myelofibrosis | Myelofibrosis with myeloid metaplasia | Chronic idiopathic myelofibrosis | International Working Group for Myelofibrosis Research and Treatment | Myeloproliferative disorders | Blast Crisis - classification | Blast Crisis - pathology | Thrombocythemia, Essential - classification | Humans | Polycythemia Vera - classification | Terminology as Topic | Primary Myelofibrosis - classification | Thrombocythemia, Essential - pathology | Primary Myelofibrosis - pathology | Cell Transformation, Neoplastic - classification | Polycythemia Vera - pathology | Cell Transformation, Neoplastic - pathology | Chronic Disease | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 12, pp. 1117 - 1127
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Humans | Middle Aged | Male | Spleen - drug effects | Dose-Response Relationship, Drug | Primary Myelofibrosis - blood | Anemia - drug therapy | Aged, 80 and over | Adult | Female | Spleen - pathology | Anemia - etiology | Janus Kinase 2 - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Cytokines - blood | Pyrazoles - adverse effects | Primary Myelofibrosis - drug therapy | Hepatomegaly - drug therapy | Primary Myelofibrosis - complications | Janus Kinase 2 - genetics | Biomarkers - blood | Janus Kinase 1 - antagonists & inhibitors | Primary Myelofibrosis - genetics | Pyrazoles - administration & dosage | STAT3 Transcription Factor - drug effects | Aged | Mutation | Hepatomegaly - etiology | Disease | Patients | Medical treatment | Risk factors | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Leukemia research, ISSN 0145-2126, 2017, Volume 59, pp. 110 - 116
Hematology, Oncology and Palliative Medicine | polycythemia vera myelofibrosis | essential thrombocythemia myelofibrosis | Primary myelofibrosis | Prognosis | Post | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Primary Myelofibrosis - mortality | Follow-Up Studies | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Survival Rate | Thrombocythemia, Essential - pathology | Primary Myelofibrosis - pathology | Disease Progression | Young Adult | Aged, 80 and over | Adult | Female | Aged | Polycythemia Vera - pathology | Pets | Anemia | Polycythemia | Leukemia | Index Medicus | post-essential thrombocythemia myelofibrosis | post-polycythemia vera myelofibrosis | primary myelofibrosis | prognosis
Journal Article
Cell stem cell, ISSN 1934-5909, 06/2017, Volume 20, Issue 6, pp. 785 - 800.e8
myeloproliferative neoplasms | myelofibrosis | Gli1 | bone marrow fibrosis | mesenchymal stem cells | Cell & Tissue Engineering | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Myofibroblasts - pathology | Primary Myelofibrosis - drug therapy | Zinc Finger Protein GLI1 - metabolism | Zinc Finger Protein GLI1 - genetics | Humans | Mice, Transgenic | Primary Myelofibrosis - pathology | Pyrimidines - pharmacology | Mesenchymal Stem Cells - pathology | Myofibroblasts - metabolism | Cell Differentiation - genetics | Primary Myelofibrosis - genetics | Animals | Cell Differentiation - drug effects | Zinc Finger Protein GLI1 - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Pyridines - pharmacology | Mesenchymal Stem Cells - metabolism | Primary Myelofibrosis - metabolism | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 10, pp. 1356 - 1363
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Predictive Value of Tests | Up-Regulation | Prognosis | Humans | Middle Aged | Male | Primary Myelofibrosis - pathology | Case-Control Studies | Protein Array Analysis - methods | Primary Myelofibrosis - blood | Interleukin-12 - blood | Aged, 80 and over | Adult | Female | Cytogenetic Analysis | Interleukin-8 - blood | Enzyme-Linked Immunosorbent Assay | Risk Assessment | Primary Myelofibrosis - immunology | Receptors, Interleukin-2 - blood | Risk Factors | Janus Kinase 2 - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Genotype | Interleukin-15 - blood | Minnesota | Chi-Square Distribution | Bone Marrow Examination | Biomarkers, Tumor - blood | Phenotype | Primary Myelofibrosis - genetics | Biopsy | Aged | Mutation | Biometrics | Index Medicus
Journal Article